

Coagulation Test Request

Client Information (required)

| Client Name | | |
|--------------------|-------------|----------|
| Client Account No. | | |
| Client Phone | Client Orde | r No. |
| Street Address | 1 | |
| City | State | ZIP Code |

Submitting Provider Information (required)

Submitting/Referring Provider (Last, First)

Fill in only if Call Back is required.

| Phone (with area code) | Fax (with area code) |
|--------------------------------|----------------------|
| Provider's National I.D. (NPI) | |

*Fax number given must be from a fax machine that complies with applicable HIPAA regulation.

Reason for Testing (required)

| 100-10 Diagitusis 0000 | ICD-10 | Diagnosis | Code |
|------------------------|--------|-----------|------|
|------------------------|--------|-----------|------|

New York State Patients: Informed Consent for Genetic Testing

"I hereby confirm that informed consent has been signed by an individual legally authorized to do so and is on file with this office or the individual's provider's office."

| Signature | |
|-----------|--|
| | |

Note: It is the client's responsibility to maintain documentation of the order.

Ship specimens to:

Mayo Clinic Laboratories 3050 Superior Drive NW Rochester, MN 55901

Customer Service: 800-533-1710

Visit www.MayoClinicLabs.com for the most up-to-date test and shipping information.

Patient Information (required)

| Patient ID (Medical Record No.) | | | |
|------------------------------------|--------------|--------------|--|
| Patient Name (Last, First, Middle) | | | |
| Sex | Birth Date (| (mm-dd-yyyy) | |
| 🗆 Male 🛛 Female | | | |
| Collection Date (mm-dd-yyyy) | Time | 🗆 am | |
| | | 🗆 pm | |
| Street Address | | | |
| City | State | ZIP Code | |
| Phone | | | |

Insurance Information

| Subscriber Name (if different than patie | ent) | |
|--|-------|----------|
| Patient Relationship | | |
| □ Spouse □ Dependent □ 0 | ther: | |
| Medicare HIC Number (if applicable) | | |
| Medicaid Number (if applicable) | | |
| Insurance Company Name (if applicable) | | |
| Insurance Company Street Address | | |
| City | State | ZIP Code |
| Policy Number | | |
| Group Number | | |
| MCL Internal Use Only | | |

Billing Information

- An itemized invoice will be sent each month.
- Payment terms are net 30 days.

Call the Business Office with billing related questions: 800-447-6424 (US and Canada) 507-266-5490 (outside the US)

Patient Information (required)

| Patient ID (Medical Record No.) | Client Account No. |
|------------------------------------|--------------------|
| Patient Name (Last, First, Middle) | Client Order No. |
| Birth Date (mm-dd-yyyy) | |

| en | | COAGULATION PROFILES |
|-----|-------------|--|
| | | |
| | ADM13 | ADAMTS13 Activity and Inhibitor Profile, Plasma |
| | ALBLD | Bleeding Diathesis Profile, Limited, Plasma |
| | CH8BP | Chromogenic Factor VIII Inhibitor Bethesda Profile, Plasma |
| | ADIC | Disseminated Intravascular Coagulation/ Intravascular Coagulation and Fibrinolysis (DIC/ICF) Profile, Plasma |
| | ALUPP | Lupus Anticoagulant Profile, Plasma |
| | APROL | Prolonged Clot Time Profile, Plasma |
| | AATHR | Thrombophilia Profile, Plasma and Whole Blood |
| | AVWPR | von Willebrand Disease Profile, Plasma |
| SP | ECIAL | COAGULATION TESTS |
| Co | agulati | on Factor Activity Testing |
| | F_2 | Coagulation Factor II Activity Assay, Plasma |
| | FACTV | Coagulation Factor V Activity Assay, Plasma |
| | F_7 | Coagulation Factor VII Activity Assay, Plasma |
| | F8A | Coagulation Factor VIII Activity Assay, Plasma |
| | F_9 | Coagulation Factor IX Activity Assay, Plasma |
| | F_10 | Coagulation Factor X Activity Assay, Plasma |
| | F_11 | Coagulation Factor XI Activity Assay, Plasma |
| | F_12 | Coagulation Factor XII Activity Assay, Plasma |
| Co | agulati | on Factor Inhibitor Profiles |
| | 2INHE | Factor II Inhibitor Evaluation, Plasma |
| | 5INHE | Factor V Inhibitor Evaluation, Plasma |
| | 7INHE | Factor VII Inhibitor Evaluation, Plasma |
| | 8INHE | Factor VIII Inhibitor Evaluation, Plasma |
| | 9INHE | Factor IX Inhibitor Evaluation, Plasma |
| | 10INE | Factor X Inhibitor Evaluation, Plasma |
| | 11INE | Factor XI Inhibitor Evaluation, Plasma |
| Inc | dividual | Tests |
| | APCRV | Activated Protein C Resistance V (APCRV), Plasma |
| | A2PI | Alpha-2 Plasmin Inhibitor, Plasma |
| | ATTF | Antithrombin Activity, Plasma |
| | ATTI | Antithrombin Antigen, Plasma |
| | FXCH | Coagulation Factor X Chromogenic Activity Assay, Plasma |
| | HITIG | Heparin-PF4 IgG Antibody, Serum |
| | PAI1 | Plasminogen Activator Inhibitor Antigen, Plasma |
| | | |
| | CFX | Protein C Activity, Plasma |
| | CFX PCAG | Protein C Activity, Plasma Protein C Antigen, Plasma |

| D PSTF | Protein S Antigen, Plasma |
|------------|---|
| □ RTSC | Reptilase Time, Plasma |
| □ TTSC | Thrombin Time (Bovine), Plasma |
| | von Willebrand Factor Activity, Plasma |
| □ VWAG | von Willebrand Factor Antigen, Plasma |
| U VWFMS | von Willebrand Factor Multimer Analysis, Plasma |
| U VWD8B | von Willebrand Disease 2N (Subtype Normandy), Plasma |
| HEREDIT | ARY THROMBOPHILIA |
| Profiles | |
| □ AATHR | Thrombophilia Profile, Plasma and Whole Blood |
| | Activated Protein C Resistance V, with Reflex to Factor V Leiden, Blood and Plasma |
| Individua | |
| □ APCRV | Activated Protein C Resistance V (APCRV), Plasma |
| □ CFX | Protein C Activity, Plasma |
| D PCAG | Protein C Antigen, Plasma |
| □ S_FX | Protein S Activity, Plasma |
| D PSTF | Protein S Antigen, Plasma |
| □ attf | Antithrombin Activity, Plasma |
| 🗆 atti | Antithrombin Antigen, Plasma |
| | D THROMBOPHILIA |
| Profiles | |
| | Lupus Anticoagulant Profile, Plasma |
| □ ALOFF | ADAMTS13 Activity and Inhibitor Profile, |
| Individua | Plasma |
| | Beta-2 Glycoprotein 1 Antibodies, lgG and lgM, Serum |
| | |
| □ DRVI1 | Dilute Russell Viper Venom Time (DRVVT), with Reflex, Plasma |
| 🗆 HITIG | Heparin-PF4 IgG Antibody (HIT), Serum |
| BLEEDIN | G DISORDERS |
| Profiles | |
| | Bleeding Diathesis Profile, Limited, Plasma |
| □ APROL | • |
| □ AVWPR | von Willebrand Disease Profile, Plasma |
| Esoteric I | Platelet Testing |
| D PTEM | Platelet Transmission Electron Microscopic Study, Whole Blood |
| 🗆 PLAFL | |

| von Willet | orand Disease |
|---|--|
| □ avwpr | von Willebrand Disease Profile, Plasma |
| □ VWACT | von Willebrand Factor Activity, Plasma |
| \Box VWAG | von Willebrand Factor Antigen, Plasma |
| U VWFMS | von Willebrand Factor Multimer Analysis, Plasma |
| Individual | Tests |
| □ F8A | Coagulation Factor VIII Activity Assay, Plasma |
| 🗆 F_9 | Coagulation Factor IX Activity Assay, Plasma |
| Chromoge | enic Tests |
| CHF8 | Chromogenic Factor VIII Activity Assay, Plasma |
| CH9 | Chromogenic Factor IX Activity Assay, Plasma |
| □ FXCH | Coagulation Factor X Chromogenic Activity Assay, Plasma |
| SPECIAL | COAGULATION DRUG ASSAYS |
| 🗆 APIXA | Apixaban, Anti-Xa, Plasma |
| □ ARGAT | Argatroban, Ecarin, Plasma |
| BIVAL | Bivalirudin, Ecarin, Plasma |
| □ RIVAR | Rivaroxaban, Anti-Xa, Plasma |
| | nivaluxadali, Altu-xa, Flasilia |
| | |
| | IVE COAGULATION TESTING |
| SUPPORT | IVE COAGULATION TESTING Beta-2 Glycoprotein 1 Antibodies, |
| SUPPORT | TVE COAGULATION TESTING Beta-2 Glycoprotein 1 Antibodies, IgG and IgM, Serum Phospholipid (Cardiolipin) Antibodies, IgG and IgM, Serum |
| SUPPORT B2GMG CLPMG THROMB(| IVE COAGULATION TESTING Beta-2 Glycoprotein 1 Antibodies, IgG and IgM, Serum Phospholipid (Cardiolipin) Antibodies, IgG and IgM, Serum DTIC MICROANGIOPATHY (TMA) |
| SUPPORT B2GMG CLPMG THROMB(| TVE COAGULATION TESTING Beta-2 Glycoprotein 1 Antibodies, IgG and IgM, Serum Phospholipid (Cardiolipin) Antibodies, IgG and IgM, Serum |
| SUPPORT B2GMG CLPMG THROMBO | IVE COAGULATION TESTING Beta-2 Glycoprotein 1 Antibodies, IgG and IgM, Serum Phospholipid (Cardiolipin) Antibodies, IgG and IgM, Serum DTIC MICROANGIOPATHY (TMA) ADAMTS13 Activity and Inhibitor Profile, |
| SUPPORT B2GMG CLPMG THROMBO | IVE COAGULATION TESTING Beta-2 Glycoprotein 1 Antibodies, IgG and IgM, Serum Phospholipid (Cardiolipin) Antibodies, IgG and IgM, Serum DTIC MICROANGIOPATHY (TMA) ADAMTS13 Activity and Inhibitor Profile, Plasma Atypical Hemolytic Uremic Syndrome (aHUS) Complement Panel, Serum and Plasma |
| SUPPORT B2GMG CLPMG THROMBO ADM13 AHUSD | IVE COAGULATION TESTING Beta-2 Glycoprotein 1 Antibodies, IgG and IgM, Serum Phospholipid (Cardiolipin) Antibodies, IgG and IgM, Serum DTIC MICROANGIOPATHY (TMA) ADAMTS13 Activity and Inhibitor Profile, Plasma Atypical Hemolytic Uremic Syndrome (aHUS) Complement Panel, Serum and Plasma Complement-Mediated Atypical Hemolytic- Uremic Syndrome (aHUS)/Thrombotic Microangiopathy (TMA) Gene Panel |
| SUPPORT B2GMG CLPMG THROMBO ADM13 AHUSD AHUSP | IVE COAGULATION TESTING Beta-2 Glycoprotein 1 Antibodies, IgG and IgM, Serum Phospholipid (Cardiolipin) Antibodies, IgG and IgM, Serum DTIC MICROANGIOPATHY (TMA) ADAMTS13 Activity and Inhibitor Profile, Plasma Atypical Hemolytic Uremic Syndrome (aHUS) Complement Panel, Serum and Plasma Complement-Mediated Atypical Hemolytic- Uremic Syndrome (aHUS)/Thrombotic Microangiopathy (TMA) Gene Panel |
| SUPPORT B2GMG CLPMG THROMB(ADM13 AHUSD AHUSP ECUMP | IVE COAGULATION TESTING Beta-2 Glycoprotein 1 Antibodies, IgG and IgM, Serum Phospholipid (Cardiolipin) Antibodies, IgG and IgM, Serum DTIC MICROANGIOPATHY (TMA) ADAMTS13 Activity and Inhibitor Profile, Plasma Atypical Hemolytic Uremic Syndrome (aHUS) Complement Panel, Serum and Plasma Complement-Mediated Atypical Hemolytic- Uremic Syndrome (aHUS)/Thrombotic Microangiopathy (TMA) Gene Panel Eculizumab Monitoring Panel, Serum |
| SUPPORT B2GMG CLPMG THROMBC ADM13 AHUSD AHUSP ECUMP ECULI | IVE COAGULATION TESTING Beta-2 Glycoprotein 1 Antibodies, IgG and IgM, Serum Phospholipid (Cardiolipin) Antibodies, IgG and IgM, Serum DTIC MICROANGIOPATHY (TMA) ADAMTS13 Activity and Inhibitor Profile, Plasma Atypical Hemolytic Uremic Syndrome (aHUS) Complement Panel, Serum and Plasma Complement-Mediated Atypical Hemolytic- Uremic Syndrome (aHUS)/Thrombotic Microangiopathy (TMA) Gene Panel Eculizumab Monitoring Panel, Serum Eculizumab, Serum |
| SUPPORT B2GMG CLPMG THROMBO ADM13 AHUSD AHUSP ECUMP ECULI RAVU | IVE COAGULATION TESTING Beta-2 Glycoprotein 1 Antibodies, IgG and IgM, Serum Phospholipid (Cardiolipin) Antibodies, IgG and IgM, Serum DTIC MICROANGIOPATHY (TMA) ADAMTS13 Activity and Inhibitor Profile, Plasma Atypical Hemolytic Uremic Syndrome (aHUS) Complement Panel, Serum and Plasma Complement-Mediated Atypical Hemolytic- Uremic Syndrome (aHUS)/Thrombotic Microangiopathy (TMA) Gene Panel Eculizumab Monitoring Panel, Serum Eculizumab, Serum Ravulizumab, Serum Ravulizumab Complement Blockage Monitoring, Serum |

Patient Information (required)

| Patient ID (Medical Record No.) | Client Account No. |
|------------------------------------|--------------------|
| Patient Name (Last, First, Middle) | Client Order No. |
| Birth Date (mm-dd-yyyy) | |

| COAGULA | TION DNA TESTING |
|---------|---|
| □ F9KMP | Hemophilia B, F9 Gene Known Mutation Analysis, Prenatal |
| □ FIXKM | Hemophilia B, F9 Gene Known Mutation, Whole Blood |
| □ F822B | Hemophilia A F8 Gene, Intron 22 Inversion Known Mutation, Whole Blood |
| □ F81B | Hemophilia A F8 Gene, Intron 1 Inversion Known Mutation, Whole Blood |
| 🗆 F8INV | Hemophilia A F8 Gene, Intron 1 and 22 Inversion Mutation Analysis, Whole Blood |
| □ F8INP | Hemophilia A F8 Gene, Intron 1 and 22 Inversion Mutation Analysis, Prenatal |
| □ F81P | Hemophilia A F8 Gene, Intron 1 Inversion Known Mutation Analysis, Prenatal, Varies |
| □ F822P | Hemophilia A F8 Gene, Intron 22 Inversion Mutation Analysis, Prenatal, Varies |

| NGS TEST | TING | ADDITIONAL TESTS |
|----------|--|-------------------------------|
| □ ATNGS | Antithrombin Deficiency, SERPINC1 Gene, Next-Generation Sequencing, Varies | (INDICATE TEST CODE AND NAME) |
| □ F2NGS | F2 Gene, Next-Generation Sequencing, Varies | |
| □ F5NGS | F5 Gene, Next-Generation Sequencing, Varies | |
| ∃ F7NGS | Factor VII Deficiency, F7 Gene, Next-Generation Sequencing, Varies | |
| ☐ F8NGS | Hemophilia A, F8 Gene, Next-Generation Sequencing, Varies | |
| □ NGSF9 | Hemophilia B, F9 Gene, Next-Generation Sequencing, Varies | |
| □ F10NG | Factor X Deficiency, F10 Gene, Next-Generation Sequencing, Varies | |
| ∃ F11NG | Hemophilia C, F11 Gene, Next-Generation Sequencing, Varies | |
| ∃ F12NG | F12 Gene, Next-Generation Sequencing, Varies | |
| □ F13NG | F13A1 and F13B Genes, Next-Generation Sequencing, Varies | |
| ∃ FIBNG | Congenital Fibrinogen Disorders, FGA, FGB, and FGG Genes, Next-Generation Sequencing, Varies | |
| □ THBNG | THBD Gene, Next-Generation Sequencing, Varies | |
| □ VWFNG | von Willebrand Disease, VWF Gene, Next-Generation Sequencing, Varies | |
| □ PCNGS | Protein C Deficiency, PROC Gene, Next-Generation Sequencing, Varies | |
| □ PRSNG | Protein S Deficiency, PROS1 Gene, Next-Generation Sequencing, Varies | |
| □ PRCNG | PROCR Gene, Next-Generation Sequencing, Varies | |